Dr. Kim on The Evaluation of TKI/Immunotherapy Combos in HCC
Richard Kim, MD, discusses the evaluation of TKI and immunotherapy combination regimens in hepatocellular carcinoma.
Dr. Shroff on the Utility of the HIMALAYA Regimen in HCC
Rachna T. Shroff, MD, MS, discusses the utility of combining anti–CTLA-4 and anti–PD-1 therapies in hepatocellular carcinoma.
Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCC
Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.
Dr. Abou-Alfa on Analyzing Disease Factors to Inform Clinical Decisions in HCC
Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.
Dr. Goff on Leveraging Clinical Trial Information to Inform Treatment Decisions in HCC
Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.
Dr. Shroff on Remaining Unmet Needs for Patients With HCC
Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.
Dr. Kim on the Evolution of Frontline Treatment in HCC
Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.